Novartis Pharma Stein has sold a building right on part of its industry area in Stein to Lonza. The SIX-listed Lonza Group has announced that it plans to construct a large-scale, commercial drug product fill & finish facility in the Stein building. The investment will allow Lonza to provide customers with a complete and integrated end-to-end solution that includes commercial drug manufacturing for large-scale market supply. The new facility will be funded by an investment of approx. CHF 500 million and is expected to be completed in 2026.
Lenz & Staehelin is advising Lonza in this transaction. The team includes Fabiano Menghini (partner, co-head of real estate, pictured), associate Rebecca Rötheli as well as Noémie Ammann and Jan Küng.
Bär & Karrer acted as legal advisor to Novartis in this transaction. The team included Corrado Rampini and Kilian Müller (both real estate).